Note
|
March 31, 2019
|
December 31, 2018
|
|||||||||
Assets
|
|||||||||||
Current Assets:
|
|||||||||||
Cash and cash equivalents
|
$
|
23,610,440
|
$
|
11,471,243
|
|||||||
Amounts receivable
|
129,546
|
143,225
|
|||||||||
Deposits
|
7
|
10,202,650
|
8,541,630
|
||||||||
Prepaid expense
|
517,169
|
586,581
|
|||||||||
Total Current Assets
|
$
|
34,459,805
|
$
|
20,742,679
|
|||||||
Patent Rights
|
3
|
1,220,068
|
1,172,485
|
||||||||
Total Assets
|
$
|
35,679,873
|
$
|
21,915,164
|
|||||||
Liabilities
|
|||||||||||
Current Liabilities:
|
|||||||||||
Accounts payable and accrued liabilities
|
4
|
$
|
6,495,644
|
$
|
6,447,888
|
||||||
Warrant liability
|
2b, 5
|
33,774,970
|
11,250,167
|
||||||||
Total Liabilities
|
$
|
40,270,614
|
$
|
17,698,055
|
|||||||
Shareholders' Equity (Deficiency)
|
|||||||||||
Share Capital
|
6
|
$
|
189,726,067
|
$
|
170,502,394
|
||||||
Contributed Surplus
|
6,903,766
|
6,652,409
|
|||||||||
Deficit
|
(201,220,574
|
)
|
(172,937,694
|
)
|
|||||||
Total Equity / Deficiency
|
$
|
(4,590,741
|
)
|
$
|
4,217,109
|
||||||
Total Liabilities and Equity / (Deficiency)
|
$
|
35,679,873
|
$
|
21,915,164
|
|||||||
Commitments (Note 7)
|
|||||||||||
See notes to financial statements
|
|||||||||||
Approved on behalf of the Board:
|
||
John E. Barker
|
David McNally
|
|
Chairman
|
President and CEO
|
Share Capital
|
Contributed
|
Total
|
|||||||||||||||||||||||||
|
Note
|
Number
|
Amount
|
Surplus
|
Warrants
|
Deficit
|
Equity
|
||||||||||||||||||||
Balance - December 31, 2017
|
12,686,723
|
$
|
154,016,519
|
$
|
5,146,784
|
$
|
741,917
|
$
|
(150,298,422
|
)
|
$
|
9,606,798
|
|||||||||||||||
Issued for Services
|
7,500
|
66,234
|
-
|
-
|
-
|
66,234
|
|||||||||||||||||||||
Warrants exercised during the period
|
6,500
|
58,448
|
-
|
-
|
-
|
58,448
|
|||||||||||||||||||||
Warrants expired during the period
|
-
|
741,917
|
-
|
(741,917
|
)
|
-
|
-
|
||||||||||||||||||||
Stock based compensation
|
-
|
-
|
367,057
|
-
|
-
|
367,057
|
|||||||||||||||||||||
Net and Comprehensive loss
|
-
|
-
|
-
|
-
|
(808,699
|
)
|
(808,699
|
)
|
|||||||||||||||||||
Balance - March 31, 2018
|
12,700,723
|
$
|
154,883,118
|
$
|
5,513,841
|
$
|
-
|
$
|
(151,107,121
|
)
|
$
|
9,289,838
|
|||||||||||||||
Balance - December 31, 2018
|
21,675,849
|
$
|
170,502,394
|
$
|
6,652,409
|
$
|
-
|
$
|
(172,937,694
|
)
|
$
|
4,217,109
|
|||||||||||||||
Issued pursuant to agency agreement
|
6a
|
8,455,882
|
13,717,131
|
-
|
-
|
-
|
13,717,131
|
||||||||||||||||||||
Share issue expense
|
(1,495,501
|
)
|
-
|
-
|
-
|
(1,495,501
|
)
|
||||||||||||||||||||
Warrants exercised during the year
|
6a
|
1,018,506
|
7,002,043
|
-
|
-
|
7,002,043
|
|||||||||||||||||||||
Stock based compensation
|
6b
|
-
|
-
|
251,357
|
-
|
-
|
251,357
|
||||||||||||||||||||
Net and Comprehensive loss
|
-
|
-
|
-
|
-
|
(28,282,880
|
)
|
(28,282,880
|
)
|
|||||||||||||||||||
Balance - March 31, 2019
|
31,150,237
|
$
|
189,726,067
|
$
|
6,903,766
|
$
|
-
|
$
|
(201,220,574
|
)
|
$
|
(4,590,741
|
)
|
Three Months Ended
|
Three Months Ended
|
||||||||||
Note
|
March 31, 2019
|
March 31, 2018
|
|||||||||
Revenue:
|
$
|
-
|
$
|
-
|
|||||||
Expenses:
|
|||||||||||
Amortization
|
$
|
6,175
|
$
|
11,742
|
|||||||
Consulting fees
|
269,429
|
230,112
|
|||||||||
Stock based compensation
|
6b
|
251,357
|
367,057
|
||||||||
Insurance
|
118,489
|
9,057
|
|||||||||
Management salaries and fees
|
648,586
|
709,024
|
|||||||||
Marketing and investor relations
|
106,189
|
44,617
|
|||||||||
Office and general
|
117,271
|
106,174
|
|||||||||
Professional fees
|
103,385
|
145,780
|
|||||||||
Rent
|
12,236
|
24,794
|
|||||||||
Research and Development
|
14,408,612
|
3,274,074
|
|||||||||
Travel
|
67,364
|
72,287
|
|||||||||
Foreign exchange (gain)/loss
|
(107,642
|
)
|
(515,153
|
)
|
|||||||
$
|
16,001,451
|
$
|
4,479,565
|
||||||||
Finance Income (cost):
|
|||||||||||
0
|
|||||||||||
Interest
|
$
|
23,031
|
$
|
28,292
|
|||||||
Gain (Loss) on change in fair value of warrants
|
2b, 5
|
(10,476,625
|
)
|
3,642,574
|
|||||||
Warrant liability issue cost
|
(1,827,835
|
)
|
-
|
||||||||
$
|
(12,281,429
|
)
|
$
|
3,670,866
|
|||||||
Net and Comprehensive Loss For The Year
|
$
|
28,282,880
|
$
|
808,699
|
|||||||
Basic and Diluted Loss Per Share
|
$
|
(1.22
|
)
|
$
|
(0.07
|
)
|
|||||
Weighted Average Number of Common Shares,
|
|||||||||||
Basic and Diluted
|
23,185,888
|
12,696,399
|
Three Months Ended
|
Three Months Ended
|
|||||||
March 31, 2019
|
March 31, 2018
|
|||||||
Cash provided by (used in):
|
||||||||
Operating activities:
|
||||||||
Net loss for the period
|
$
|
(28,282,880
|
)
|
$
|
(808,699
|
)
|
||
Items not involving cash:
|
||||||||
Amortization
|
6,175
|
11,742
|
||||||
Stock based compensation
|
251,357
|
367,057
|
||||||
Other share compensation
|
-
|
66,234
|
||||||
Warrant liability-fair value adjustment
|
10,476,625
|
(3,642,574
|
)
|
|||||
Warrant liability-foreign exchange adjustment
|
(106,057
|
)
|
(514,355
|
)
|
||||
Changes in non-cash working capital items:
|
||||||||
Amounts receivable, prepaid expenses and deposits
|
(1,577,929
|
)
|
(1,808,310
|
)
|
||||
Accounts payable and accrued liabilities
|
47,756
|
695,839
|
||||||
Cash used in operating activities
|
$
|
(19,184,953
|
)
|
$
|
(5,633,066
|
)
|
||
Financing activities:
|
||||||||
Net proceeds from issuance of common shares and warrants
|
$
|
31,377,908
|
$
|
29,500
|
||||
Cash provided by financing activities
|
$
|
31,377,908
|
$
|
29,500
|
||||
Investing Activities:
|
||||||||
Cost of Patents
|
$
|
(53,758
|
)
|
$
|
(56,548
|
)
|
||
Cash used in investing activities
|
$
|
(53,758
|
)
|
$
|
(56,548
|
)
|
||
Increase (Decrease) in cash and cash equivalents
|
$
|
12,139,197
|
$
|
(5,660,114
|
)
|
|||
Cash and cash equivalents, beginning of the period
|
11,471,243
|
26,130,493
|
||||||
Cash and cash equivalents, end of the period
|
$
|
23,610,440
|
$
|
20,470,379
|
||||
Cash and cash equivalents comprise:
|
||||||||
Cash
|
$
|
582,622
|
$
|
227,964
|
||||
Cash Equivalents
|
23,027,818
|
20,242,415
|
||||||
$
|
23,610,440
|
$
|
20,470,379
|
1.
|
DESCRIPTION OF BUSINESS
|
(a)
|
Statement of Compliance
|
(b)
|
Basis of Measurement
|
(c)
|
Functional and Presentation Currency
|
2.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
|
(a)
|
Use of Estimates and Judgements
|
(b)
|
Warrant Liability
|
(c)
|
Fair Value Measurement
|
2.
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued) |
(d)
|
Adoption of New Accounting Standard
|
3.
|
PATENT
RIGHTS
|
Cost
|
||||
Balance at December 31, 2018
|
$
|
1,398,713
|
||
Additions
|
53,758
|
|||
Balance at December 31, 2019
|
$
|
1,452,471
|
||
|
||||
Amortization & Impairment Losses
|
||||
Balance at December 31, 2018
|
$
|
226,228
|
||
Amortization for the period
|
6,175
|
|||
Balance at December 31, 2019
|
$
|
232,403
|
||
|
||||
Net Book Value
|
||||
At December 31, 2018
|
$
|
1,172,485
|
||
At December 31, 2019
|
$
|
1,220,068
|
4.
|
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES |
5. | WARRANT LIABILITY |
Quarter Ended
|
Year Ended
|
|||||||||||||||
March 31, 2019
|
December 31, 2018
|
|||||||||||||||
Number of
|
Number of
|
|||||||||||||||
Warrants
|
Amount
|
Warrants
|
Amount
|
|||||||||||||
Opening Balance
|
13,901,859
|
$
|
11,250,167
|
4,933,231
|
$
|
17,849,460
|
||||||||||
Issue of warrants expiring, April 10, 2023
|
-
|
-
|
1,295,554
|
5,212,087
|
||||||||||||
Issue of warrants expiring, August 10, 2023
|
-
|
-
|
7,679,574
|
6,297,251
|
||||||||||||
Issue of warrants expiring, March 20, 2023
|
8,455,882
|
15,897,059
|
-
|
-
|
||||||||||||
Warrants exercised during the period
|
(1,018,506
|
)
|
(3,742,824
|
)
|
(6,500
|
)
|
(28,949
|
)
|
||||||||
Warrants expired during the period
|
(135,824
|
)
|
-
|
-
|
-
|
|||||||||||
Foreign exhange adjustment during the period
|
-
|
(106,057
|
)
|
-
|
(984,462
|
)
|
||||||||||
Fair value adjustment during the period
|
-
|
10,476,625
|
-
|
(17,095,220
|
)
|
|||||||||||
Ending Balance
|
21,203,411
|
$
|
33,774,970
|
13,901,859
|
$
|
11,250,167
|
6. | SHARE CAPITAL |
a)
|
Authorized:
|
unlimited number of common shares, no par
|
|
|
|
|
|
|
Issued:
|
31,150,237 (December 31, 2018: 21,675,849)
|
|
Three Months ended
March 31, 2019
|
Year ended
December 31, 2018
|
|||
Number of
Stock Options
|
Weighted average
Exercise Price (CDN)
|
Number of
Stock Options
|
Weighted average
Exercise Price (USD)
|
|
Balance Beginning
|
875,433
|
$ 18.20
|
591,609
|
$ 21.30
|
Granted 2
|
-
|
-
|
322,517
|
$ 13.51
|
Expired/Forfeited
|
-
|
-
|
(38,693)
|
$ 24.90
|
Balance Ending
|
875,433
|
$ 18.20
|
875,433
|
$ 18.20
|
Three Months ended
March 31, 2019
|
Year ended
December 31, 2018
|
|||
Number of
Stock Options
|
Weighted average
Exercise Price (USD)
|
Number of
Stock Options |
Weighted average
Exercise Price (USD)
|
|
Balance Beginning
|
50,349
|
1.55
|
-
|
-
|
Granted 2
|
40,000
|
3.72
|
50,349
|
$ 1.55
|
Expired/Forfeited
|
-
|
-
|
-
|
-
|
Balance Ending
|
90,349
|
2.51
|
50,349
|
$ 1.55
|
1.
|
After giving consideration for 30:1 share consolidation effected June 2018.
|
2.
|
Options granted to a consultant in March 2019 will vest in accordance with a vesting schedule and milestones achieved over
a 15-month period. Accordingly, the Company will recognize expense for these Options as the service is provided and the milestones achieved.
|
Canadian Dollar Denominated Options
|
||||||||||||
Exercise
Price (CDN)
|
Number
Outstanding
|
Weighted-average
remaining contractual life
(years)
|
Options
Exercisable
|
|||||||||
$3.28
|
31,498
|
6.50
|
31,498
|
|||||||||
$4.50
|
18,935
|
4.30
|
18,935
|
|||||||||
$4.80
|
3,040
|
1.55
|
3,040
|
|||||||||
$7.49
|
5,590
|
6.36
|
5,590
|
|||||||||
$9.00
|
11,481
|
6.36
|
11,481
|
|||||||||
$9.60
|
1,105
|
1.61
|
1,105
|
|||||||||
$11.70
|
6,667
|
1.77
|
6,667
|
|||||||||
$12.00
|
1,948
|
1.77
|
1,948
|
|||||||||
$12.90
|
50,000
|
5.14
|
28,125
|
|||||||||
$14.40
|
18,950
|
5.70
|
6,317
|
|||||||||
$15.00
|
16,667
|
4.95
|
8,681
|
|||||||||
$15.00
|
273,948
|
5.90
|
114,145
|
|||||||||
$17.10
|
277,519
|
4.89
|
86,725
|
|||||||||
$30.00
|
105,719
|
2.49
|
92,192
|
|||||||||
$30.60
|
6,120
|
1.82
|
6,120
|
|||||||||
$32.40
|
18,810
|
1.92
|
18,810
|
|||||||||
$41.70
|
658
|
0.80
|
658
|
|||||||||
$45.30
|
560
|
1.45
|
560
|
|||||||||
$51.60
|
15,371
|
1.28
|
15,371
|
|||||||||
$58.20
|
10,848
|
0.22
|
10,848
|
|||||||||
875,433
|
4.76
|
468,814
|
||||||||||
US Dollar Denominated Options
|
||||||||||||
Exercise
Price (USD)
|
Number
Outstanding
|
Weighted-average
remaining contractual life
(years)
|
Options
Exercisable
|
|||||||||
$1.55
|
50,349
|
2.81
|
50,349
|
|||||||||
$3.72
|
40,000
|
2.72
|
-
|
|||||||||
90,349
|
2.77
|
50,349
|
||||||||||
Grant date/ Recipient
|
Number of
Options 1
|
Vesting Conditions
|
Contractual Life
of Options
|
January 17, 2017, option grants to Employees
|
277,519
|
Vest as to ¼ of the total number of Options granted, every year from Option Date
|
7 years
|
February 7, 2017 option grants to Employees
|
16,667
|
Vest as to ¼ of the total number of Options granted, every year from Option Date
|
7 years
|
April 17, 2017, options granted to Employees
|
50,000
|
Vest as to ¼ of the total number of Options granted, every year from Option Date
|
7 years
|
September 7, 2017, options granted to Consultants
|
6,667
|
Half vest in 3 months and the remaining half in 6 months
|
3 years
|
September 7, 2017, options granted to Directors
|
12,269
|
immediately
|
7 years
|
September 15,2017, options granted to Consultants
|
3,040
|
immediately
|
3 years
|
October 6, 2017, options granted to Consultants
|
1,105
|
immediately
|
3 years
|
November 8, 2017 options granted to Employees
|
18,950
|
Vest as to ¼ of the total number of Options granted, every year from Option Date
|
7 years
|
December 4, 2017, options granted to Consultants
|
1,948
|
immediately
|
3 years
|
December 4, 2017, options granted to Consultants
|
6,667
|
Half vest immediately and the remaining half in 12 months
|
3 years
|
January 19, 2018 options granted to Employees
|
273,948
|
Options will vest the earlier of commercialization or 3 years from grant date
|
7 years
|
July 6, 2018, options granted to Directors
|
17,071
|
immediately
|
7 years
|
August 29, 2018, options granted to Directors
|
31,498
|
immediately
|
7 years
|
December 18, 2018, options granted to Consultants
|
50,349
|
immediately
|
3 years
|
February 14, 2019, options granted to a Consultant
|
40,000
|
Options may vest over a 15-month vesting schedule
|
3 years
|
1.
|
After giving effect of the 30:1 share consolidation of June 2018.
|
2.
|
Options granted to a consultant in March 2019 will vest in accordance with a vesting schedule and milestones achieved over a 15-month period. Accordingly, the Company will recognize expense for these Options as the service is provided and the milestones achieved. |
2019
|
2018
|
|||||
Fair Value at grant
|
-
|
$5.99
|
||||
Share price at grant
|
-
|
$10.79
|
||||
Exercise price
|
-
|
CDN $11.97
|
||||
Expected Volatility
|
-
|
90.12%
|
||||
Option Life
|
-
|
3 years
|
||||
Expected dividends
|
-
|
nil
|
||||
Risk free interest rate (based on government bonds)
|
-
|
1.90%
|
March 31, 2019
|
December 31, 2018
|
|||||||||||||||
Number of Shares
|
%
|
Number of Shares
|
%
|
|||||||||||||
John Barker
|
32,714
|
0.11
|
31,714
|
0.15
|
||||||||||||
David McNally
|
4,167
|
0.01
|
4,167
|
0.02
|
||||||||||||
Stephen Randall
|
22,993
|
0.07
|
21,643
|
0.10
|
||||||||||||
John Schellhorn
|
294
|
0.00
|
294
|
-
|
||||||||||||
Bruce Wolff
|
7,610
|
0.02
|
7,610
|
0.03
|
||||||||||||
Total
|
67,778
|
0.22
|
65,428
|
0.30
|
||||||||||||
Common Shares Outstanding
|
31,150,237
|
100
|
%
|
21,675,849
|
100
|
%
|